Markets:

Overview

News

Currencies

International

Treasuries

Churchill Capital Corp XI - Class A Ordinary Shares (NQ:CCXI)

16.33 +2.47 (+17.82%)

Streaming Delayed Price Updated: 3:22 PM EDT, Jun 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Churchill Capital Corp XI - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

The trading volume of these stocks is deviating from the norm in today's session. ↗

Today 13:00 EDT

Via Chartmill

The trading volume of these stocks is deviating from the norm in today's session. ↗

June 26, 2026

Via Chartmill

These stocks have an unusual volume in today's session ↗

June 25, 2026

Via Chartmill

Agility Robotics to Go Public Through $2.5 Billion Merger with Churchill Capital Corp XI

June 24, 2026

From Agility Robotics, Inc.

Via Business Wire

Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share ↗

December 12, 2022

Via Benzinga

ChemoCentryx: Q2 Earnings Insights ↗

August 09, 2022

ChemoCentryx (NASDAQ:CCXI) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

3 Analysts Have This to Say About ChemoCentryx ↗

August 05, 2022

ChemoCentryx (NASDAQ:CCXI) has observed the following analyst ratings within the last quarter:

Via Benzinga

How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market ↗

November 23, 2022

Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years.

Via Benzinga

ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings

October 17, 2022

From ChemoCentryx, Inc.

Via GlobeNewswire

Biotech Stocks Well-Positioned For The Fourth Quarter ↗

October 12, 2022

The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.

Via Talk Markets

ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 05, 2022

From ChemoCentryx, Inc.

Via GlobeNewswire

These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022 ↗

September 20, 2022

We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022.

Via Talk Markets

Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year ↗

September 19, 2022

The biotech run off a June bottom is great — until you realize you could've netted more.

Via Investor's Business Daily

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗

September 15, 2022

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

Via Investor's Business Daily

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI

September 13, 2022

From Scott+Scott Attorneys at Law LLP

Via Business Wire

7 Dow Stocks With Superior Fundamentals ↗

September 06, 2022

Robust Dow stocks offer attractive deals for patient investors amidst an unstable economic environment

Via InvestorPlace

Healthcare Sector Still Looks Good But Lacks Momentum ↗

September 06, 2022

The summer rally is over it’s a holiday weekend with low trading volume and bad news is pervasive. A decent jobs report on Friday brought in buyers in early hours until Russia intervened with a Nord...

Via Talk Markets

ChemoCentryx's Return On Capital Employed Insights ↗

September 01, 2022

According to data from Benzinga Pro, during Q2, ChemoCentryx's (NASDAQ:CCXI) reported sales totaled $11.76 million. Despite a 18.02% increase in earnings, the company posted a loss of $31.65 million.

Via Benzinga

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI

August 30, 2022

From Scott+Scott Attorneys at Law LLP

Via Business Wire

10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others ↗

August 29, 2022

These names are benefitting from M&A, clinical data and promising regulatory actions.

Via Investor's Business Daily

Whither Small Caps After Fed’s Tough Talk? ↗

August 29, 2022

For now its better not to “Fight the Fed” because they are fighting the with the market. Now that everyone is scared of the Fed's rhetoric it would be better to wait a week or so as more data and...

Via Talk Markets

Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million ↗

August 23, 2022

The biopharma buying spree continued Tuesday with glaucoma drugs maker Aerie.

Via Investor's Business Daily

Check your Portfolio for Small Cap Weighting: Growth, Innovation or Speculation? ↗

August 15, 2022

The SPDR S&P Biotech ETF remains our key indicator for small cap biotechs. It is up 14.55% over one month at $93.78 but is still down 16% YTD. The Russell 2000 is up 16.5% over one month mirroring...

Via Talk Markets

Why Jim Cramer Says This Financial Stock Is 'Terrific' ↗

August 12, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said The Charles Schwab Corporation (NYSE: SCHW) is "terrific."

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022 ↗

August 10, 2022

Via Benzinga

Earnings Preview: ChemoCentryx ↗

August 08, 2022

ChemoCentryx (NASDAQ:CCXI) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. Analysts estimate that ChemoCentryx...

Via Benzinga

Small Cap Biotechs Perk Up On Dealmaking ↗

August 06, 2022

With M&A picking up we would think smaller deals make sense for large cap biopharma to expand pipelines and complement technology.

Via Talk Markets

Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review ↗

August 05, 2022

The Nasdaq and small caps rose while the S&P 500 is hitting resistance.

Via Investor's Business Daily

Where ChemoCentryx Stands With Analysts ↗

August 05, 2022

Over the past 3 months, 4 analysts have published their opinion on ChemoCentryx (NASDAQ:CCXI) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022 ↗

August 05, 2022

Upgrades

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.